Candel Therapeutics (CADL) Amortization of Deferred Charges (2020 - 2025)
Candel Therapeutics (CADL) reported Amortization of Deferred Charges of $35000.0 for Q4 2025, up 16.67% on a YoY basis from $30000.0 in Q4 2024, and up 2.94% sequentially from $34000.0 in Q3 2025.
Candel Therapeutics (CADL) Amortization of Deferred Charges (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Amortization of Deferred Charges data on file, last reported at $35000.0 in Q4 2025.
- For the quarter ending Q4 2025, Amortization of Deferred Charges rose 16.67% year-over-year to $35000.0; the trailing twelve-month figure through Dec 2025 stood at $138000.0 (up 15.97% YoY), and the FY2025 full-year result was $138000.0, up 15.97% from the prior year.
- Amortization of Deferred Charges climbed to $35000.0 in Q4 2025, from $34000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $35000.0 in Q2 2025 to a low of $18000.0 in Q4 2021.
- A 5-year average of $26250.0 and a median of $26000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- Across the five-year window, Amortization of Deferred Charges surged 205.88% in 2021 and climbed 10.0% in 2022, its largest moves.
- Tracing CADL's Amortization of Deferred Charges over 5 years: stood at $18000.0 in 2021, then advanced by 27.78% to $23000.0 in 2022, then gained by 13.04% to $26000.0 in 2023, then climbed by 15.38% to $30000.0 in 2024, then climbed by 16.67% to $35000.0 in 2025.
- Business Quant data shows CADL's Amortization of Deferred Charges at $35000.0 in Q4 2025, $34000.0 in Q3 2025, and $35000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn |
| 10 | Candel Therapeutics | 517.94 Mn | 517.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 35,000.00 |
| Dec 31, 2025 | 35,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Jun 30, 2025 | 35,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 29,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | 26,000.00 |
| Sep 30, 2023 | 26,000.00 |